BIBF1120 (Vargatef) Inhibits Preretinal Neovascularization and Enhances Normal Vascularization in a Model of Vasoproliferative Retinopathy

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 13, 2015, Pages 7897-7907

  Rivera, José Carlos ^a,b   Noueihed, Baraa ^a   Omri, Samy ^a   Barrueco, Jose ^c   Hilberg, Frank ^d   Chemtob, Sylvain ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

Antiangiogenic; BIBF1120; Neovascularization; Nintedanib; Retinopathy of prematurity; Tyrosine kinase inhibitor; Vargatef

Indexed keywords

DELTA LIKE LIGAND 4; EPHRIN B2; EPHRIN RECEPTOR B4; GENOMIC DNA; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NETRIN 1; NINTEDANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; INDOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTIC MICROVASCULAR SPROUTING ASSAY; AORTIC RING ASSAY; ARTICLE; CONTROLLED STUDY; DATA PROCESSING; DRUG EFFICACY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; MICROPHOTOGRAPHY; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA GANGLION CELL; RETINA NEOVASCULARIZATION; RNA EXTRACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; NEWBORN; PATHOLOGY; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; FEMALE; INDOLES; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY;

EID: 84950326794     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17146     Document Type: Article

References (86)

1. Gilbert C, Rahi J, Eckstein M, O’Sullivan J, Foster A. Retinopathy of prematurity in middle-income countries. Lancet. 1997;350:12-14.
2. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust. 1951;2:48-50.
3. Patz A, Hoeck LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol. 1952;35:1248-1253.
4. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38:397-432.
5. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118:526-533.
6. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009;50:1329-1335.
7. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804-5808.
8. Wilkinson-Berka JL, Babic S, De Gooyer T, et al. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol. 2004;164: 1263-1273.
9. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:2165-2169.
10. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expres- sion in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
11. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116: 1599-1603.
12. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med. 2011;364:1897-1908.
13. Kovach JL, Schwartz SG, Flynn HW Jr, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012: 786870.
14. Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol. 2011;89:405-411.
15. Vavvas DG. Anti-VEGF in retinopathy of prematurity, need to titrate. Invest Ophthalmol Vis Sci. 2013;54.
16. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
17. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One. 2008;3: e3554.
18. Ford KM, Saint-Geniez M, Walshe TE, D’Amore PA. Expression and role of VEGF-a in the ciliary body. Invest Ophthalmol Vis Sci. 2012;53:7520-7527.
19. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest. 2012;122:4213-4217.
20. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168:2036-2053.
21. Li JL, Sainson RC, Oon CE, et al. DLL4-Notch signalling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71:6073-6083.
22. Joyal JS, Sitaras N, Binet F, et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphoring 3A. Blood. 2011;117:6024-6035.
23. Segarra M, Ohnuki H, Maric D, et al. Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood. 2012;120: 4104-4115.
24. Rivera JC, Sitaras N, Noueihed B, et al. Microglia and interleukin-1beta in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3A. Arterioscler Thromb Vasc Biol. 2013;33:1881-1891.
25. Gagliardini V, Fankhauser C. Semaphorin III can induce death in sensory neurons. Mol Cell Neurosci. 1999;14:301-316.
26. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem. 2007;282:26294-26305.
27. Jones CA, London NR, Chen H, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med. 2008;14:448-453.
28. Salvucci O, Maric D, Economopoulou M, et al. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood. 2009;114:1707-1716.
29. Binet F, Mawambo G, Sitaras N, et al. Neuronal ER stress impedes myeloid-cell-induced vascular regeneration through IRE1alpha degradation of netrin-1. Cell Metab. 2013;17:353-371.
30. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361-370.
31. Larrieu-Lahargue F, Welm AL, Bouchecareilh M, et al. Blocking fibroblast growth factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PLoS One. 2012; 7:e39540.
32. Davies MH, Stempel AJ, Hubert KE, Powers MR. Altered vascular expression of EphrinB2 and EphB4 in a model of oxygen-induced retinopathy. Dev Dyn. 2010;239:1695-1707.
33. Iso T, Maeno T, Oike Y, et al. Dll4-selective Notch signalling induces ephrinB2 gene expression in endothelial cells. Biochem Biophys Res Commun. 2006;341:708-714.
34. Gale NW, Baluk P, Pan L, et al. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol. 2001;230:151-160.
35. Vihanto MM, Plock J, Erni D, Frey BM, Frey FJ, Huynh-Do U. Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J. 2005;19:1689-1691.
36. Sawamiphak S, Seidel S, Essmann CL, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010;465:487-491.
37. Nakayama A, Nakayama M, Turner CJ, Hoing S, Lepore JJ, Adams RH. Ephrin-B2 controls PDGFRbeta internalization and signaling. Genes Dev. 2013;27:2576-2589.
38. Atkinson-Leadbeater K, Bertolesi GE, Hehr CL, Webber CA, Cechmanek PB, McFarlane S. Dynamic expression of axon guidance cues required for optic tract development is controlled by fibroblast growth factor signaling. J Neurosci. 2010;30:685-693.
39. Chen J, Hicks D, Brantley-Sieders D, et al. Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res. 2006;82:664-673.
40. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111:1287-1295.
41. Tian LL, Ren B, Gao XW, et al. Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib. Int J Ophthalmol. 2014;7:198-204.
42. Thakur A, Scheinman RI, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011;82:346-350.
43. Yafai Y, Yang XM, Niemeyer M, et al. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol. 2011;666:12-18.
44. Onder HI, Erdurmus M, Bucak YY, Simavli H, Oktay M, Kukner AS. Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization. Int J Ophthalmol. 2014;7:220-225.
45. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774-4782.
46. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011;22:1374-1381.
47. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16:311-319.
48. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29:3798-3804.
49. Kutluk Cenik B, Ostapoff KT, Gerber DE, Brekken RA. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther. 2013; 12:992-1001.
50. Huu VA, Luo J, Zhu J, et al. Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. J Control Release. 2015;200: 71-77.
51. Kulimova E, Oelmann E, Bisping G, et al. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol Cancer Ther. 2006;5:3105-3112.
52. Penn JS, Tolman BL, Henry MM. Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest Ophthalmol Vis Sci. 1994;35:3429-3435.
53. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36:724-731.
54. Stahl A, Connor KM, Sapieha P, et al. Computer-aided quantification of retinal neovascularization. Angiogenesis. 2009;12:297-301.
55. Beauchamp MH, Marrache AM, Hou X, et al. Platelet-activating factor in vasoobliteration of oxygen-induced retinopathy. Invest Ophthalmol Visual Sci. 2002;43:3327-3337.
56. Zudaire E, Gambardella L, Kurcz C, Vermeren S. A computational tool for quantitative analysis of vascular networks. PLoS One. 2011;6:e27385.
57. Honore JC, Kooli A, Hamel D, et al. Fatty acid receptor Gpr40 mediates neuromicrovascular degeneration induced by transarachidonic acids in rodents. Arterioscler Thromb Vasc Biol. 2013;33:954-961.
58. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest. 1990;63:115-122.
59. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Medi. 1995;1:1024-1028.
60. Yamada H, Yamada E, Hackett SF, Ozaki H, Okamoto N, Campochiaro PA. Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina. J Cell Physiol. 1999;179:149-156.
61. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15: 4738-4747.
62. Sufen G, Xianghong Y, Yongxia C, Qian P. bFGF and PDGF-BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells. Cell Biol Int. 2011;35:545-551.
63. Testori J, Schweighofer B, Helfrich I, et al. The VEGF-regulated transcription factor HLX controls the expression of guidancecues and negatively regulates sprouting of endothelial cells. Blood. 2011;117:2735-2744.
64. Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007;104:3219-3224.
65. McFarlane S, Cornel E, Amaya E, Holt CE. Inhibition of FGF receptor activity in retinal ganglion cell axons causes errors in target recognition. Neuron. 1996;17:245-254.
66. Tolentino MJ. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med. 2009;9:973-981.
67. Eichler W, Yafai Y, Wiedemann P, Fengler D. Antineovascular agents in the treatment of eye diseases. Curr Pharm Des. 2006;12:2645-2660.
68. Rivera JC, Sapieha P, Joyal JS, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology. 2011; 100:343-353.
69. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
70. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.
71. Murakami M, Nguyen LT, Zhuang ZW, et al. The FGF system has a key role in regulating vascular integrity. J Clin Invest. 2008;118:3355-3366.
72. French WJ, Creemers EE, Tallquist MD. Platelet-derived growth factor receptors direct vascular development independent of vascular smooth muscle cell function. Mol Cell Biol. 2008;28: 5646-5657.
73. Budd SJ, Hartnett ME. Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity. Arch Ophthalmol. 2010;128:589-595.
74. Hartmann JS, Thompson H, Wang H, et al. Expression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurity. Mol Vis. 2011;17:1577-1587.
75. Wang B, Xiao Y, Ding BB, et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell. 2003;4:19-29.
76. Ehlken C, Martin G, Lange C, et al. Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproli- ferative retinopathy. Acta Ophthalmol. 2011;89:82-90.
77. Finci LI, Kruger N, Sun X, et al. The crystal structure of netrin- 1 in complex with DCC reveals the bifunctionality of netrin-1 as a guidance cue. Neuron. 2014;83:839-849.
78. Wilson BD, Ii M, Park KW, et al. Netrins promote develop- mental and therapeutic angiogenesis. Science. 2006;313:640-644.
79. Kuijper S, Turner CJ, Adams RH. Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc Med. 2007;17: 145-151.
80. Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445:776-780.
81. Shi S, Li X, Li Y, Pei C, Yang H, Chen X. Expression and function of Delta-like ligand 4 in a rat model of retinopathy of prematurity. Neural Regen Res. 2013;8:723-730.
82. Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res. 1996;15:175-184.
83. Suchting S, Freitas C, le Noble F, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A. 2007;104:3225-3230.
84. Dorfman AL, Cuenca N, Pinilla I, Chemtob S, Lachapelle P. Immunohistochemical evidence of synaptic retraction, cytoarchitectural remodeling, and cell death in the inner retina of the rat model of oygen-induced retinopathy (OIR). Invest Ophthalmol Vis Sci. 2011;52:1693-1708.
85. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther. 2010;9:2825-2833.
86. Kropff M, Kienast J, Bisping G, et al. An open-label dose- escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. Anticancer Res. 2009;29:4233-4238.